Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

K Aaboe, F K Knop, T Vilsbøll, C F Deacon, Jens Juul Holst, S Madsbad, Troels Magelund Krarup

To examine the effects of 12 weeks of treatment with the DPP-4 inhibitor, sitagliptin, on gastrointestinal hormone responses to a standardized mixed meal and beta cell secretory capacity, measured as glucose and non-glucose induced insulin secretion during a hyperglycaemic clamp, in patients with type 2 diabetes.
Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume12
Issue number4
Pages (from-to)323-33
Number of pages11
ISSN1462-8902
DOIs
Publication statusPublished - 1 Apr 2010

    Research areas

  • Adult, Aged, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Double-Blind Method, Drug Administration Schedule, Female, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptide YY, Postprandial Period, Pyrazines, Triazoles

ID: 33939951